Despite contrary results in humans it seems that SREBP-1c promotes NAFLD progression, as increased expression levels of SREBP-1c and its target enzymes FAS and ACC were determined to be elevated in NAFLD patients [125,126,127,128]. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.